Shamburg News · 8-K filed Nov 12, 2026, 8:30 AM EST
VolitionRx CEO Cameron Reynolds Agrees to Further Temporary Base Salary Reduction
VNRX · VOLITIONRX LTD
- Leadership change
- Material agreement
- Materiality: medium
On November 10, 2026, Singapore Volition Pte. Limited, a wholly-owned subsidiary of VolitionRx Limited, and CEO and President Cameron Reynolds entered into a variation letter further reducing his annual base salary temporarily. Effective November 1, 2026, his base salary decreases from $355,456 to $236,970.50 without additional equity compensation, remaining in effect until the Compensation Committee determines reinstatement. Severance and other salary-linked payments will continue to be calculated using his full contractual salary of $473,941.
Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001477932-26-006845.
Written from the filing by Shamburg Markets. Figures are as reported by the company.